Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063659 · ClinicalTrials.gov registry record · Phase 3
Telotristat Etiprate for Carcinoid Syndrome Therapy
A Phase 3 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT02063659 is a Phase 3 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT02063659, a Phase 3 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Interventions
- DRUG Placebo
- DRUG Telotristat etiprate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-03-11 |
| Est. Completion | 2016-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02063659
The ClinicalTrials.gov registry entry for NCT02063659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02063659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02063659 about?
NCT02063659 is a clinical study titled "Telotristat Etiprate for Carcinoid Syndrome Therapy". The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
What is the current status of trial NCT02063659?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2014-03-11. Estimated completion is 2016-03-29.
What interventions are being tested in trial NCT02063659?
The interventions under investigation include: Placebo (DRUG), Telotristat etiprate (DRUG).
Who is sponsoring clinical trial NCT02063659?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.